



Universiteit
Leiden

The Netherlands

Symptomatic treatment of myasthenia gravis and its role in the era of emerging immunomodulatory treatments

Remijn-Nelissen; L.

Citation

Symptomatic treatment of myasthenia gravis and its role in the era of emerging immunomodulatory treatments. (2026, September 3). *Symptomatic treatment of myasthenia gravis and its role in the era of emerging immunomodulatory treatments.* Retrieved from <https://hdl.handle.net/1887/4309162>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4309162>

Note: To cite this publication please use the final published version (if applicable).

Linda Remijn-Nelissen

Symptomatic treatment of myasthenia gravis

and its role in the era of emerging immunomodulatory treatments

Symptomatic treatment of myasthenia gravis

and its role in the era of emerging immunomodulatory treatments

The research presented in this thesis was performed at the Department of Neurology of the Leiden University Medical Center.

Coverdesign & lay-out: Wendy Schoneveld, www.wenzid.nl

Printing: ProefschriftMaken, www.proefschriftmaken.nl

ISBN: 978-94-6534-541-3

Copyright © Linda Remijn-Nelissen, Leiden, 2026.

All rights reserved. No part of this thesis may be reproduced, stored, or transmitted in any form or by any means without prior permission of the author, or the copyright-owning journals for previously published chapters.

Financial support: The research projects described in chapters 3 and 4 were (partially) supported by unrestricted funding from NMD Pharma. The work in chapter 4 was also supported by a grant from the Netherlands Organisation for Health Research and Development (ZonMw, The Hague, The Netherlands; grant number 10140022110010, granted to Dr. M.R. Tannemaat, paid to institution). The project described in chapter 6 was partially supported by unrestricted funding from UCB Pharma. The funders had no role in the study design, data collection, data analysis, data interpretation, the writing of the manuscripts, or the decision to publish.

Symptomatic treatment of myasthenia gravis and its role in the era of emerging immunomodulatory treatments

Proefschrift

ter verkrijging van
de graad van doctor aan de Universiteit Leiden,
op gezag van rector magnificus prof.dr. S. de Rijcke,
volgens besluit van het college voor promoties
te verdedigen op donderdag 3 september 2026
klokke 11.30 uur

door

Linda Remijn-Nelissen

geboren te Heesch
in 1988

Promotores

Prof. dr. J.J.G.M. Verschuuren
Prof. dr. T. van Gelder

Copromotor

Dr. M.R. Tannemaat

Leden promotiecommissie

Prof. dr. ir. S.M. van der Maarel
Prof. dr. H.J. Guchelaar
Dr. C. Barnett-Tapia (University of Toronto)
Dr. A.M. Dekker (Universitair Medisch Centrum Utrecht)

Table of Contents

CHAPTER 1	General introduction, aims and thesis outline	7
------------------	---	---

PART I SYMPTOMATIC TREATMENT

CHAPTER 2	Symptomatic pharmacological treatment <i>RRNMF Neuromuscular Journal (2023)</i>	23
------------------	--	----

CHAPTER 3	The effectiveness and side effects of pyridostigmine <i>Neuromuscular disorders (2022)</i>	35
------------------	---	----

CHAPTER 4	Efficacy and cost-utility of pyridostigmine <i>Neurology (2026)</i>	57
------------------	--	----

CHAPTER 5	Efficacy and safety of amifampridine <i>Neurology (2026)</i>	81
------------------	---	----

PART II IMMUNOMODULATORY THERAPIES

CHAPTER 6	Treatment patterns in myasthenia gravis <i>Journal of neuromuscular diseases (2026)</i>	107
------------------	--	-----

CHAPTER 7	Efgartigimod in refractory myasthenia gravis <i>Muscle & nerve (2024)</i>	121
------------------	--	-----

CHAPTER 8	Summary, general discussion and future perspectives	135
------------------	---	-----

REFERENCES	149
-------------------	-----

APPENDICES

Nederlandse samenvatting	160
List of publications	164
Dankwoord	166
Curriculum vitae	168